U.S. medical researchers report a possible breakthrough that might prevent infection by one of the two most widespread varieties of malaria.
A new class of anti-malaria compounds kills the parasites in the developmental stages in the liver, before they get into the bloodstream.
The compounds proved highly successful in animal tests, according to a study published in Science, but their effectiveness in humans is still uNPRoven.
Plasmodium vivax is the dominant strain of the malaria parasite outside Africa. Unlike the more deadly Plasmodium falciparum, vivax can infect a person bu
